SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation Covering SCI-110
Benzinga Newsdesk 2 months ago
FDANewsBiotechGeneral
This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing new treatment
This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing new treatment options for adult Tourette Syndrome